Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma

被引：47
|
作者：
Kudo, Masatoshi [1 ]
机构：
[1] Kindai Univ, Fac Med, Dept Gastroenterol & Hepatol, Osaka, Japan
来源：
LIVER CANCER | 2022年 / 11卷 / 05期
关键词：
Atezolizumab plus bevacizumab; Hepatocellular carcinoma; ABC conversion; Curative therapy; Cancer-free status; Drug-free status; POSITRON-EMISSION-TOMOGRAPHY; T-CELL RESPONSES; RADIOFREQUENCY ABLATION; F-18-FDG PET/CT; TUMOR; LENVATINIB; DIFFERENTIATION; IDENTIFICATION; ENHANCEMENT; MULTICENTER;
D O I：
10.1159/000526163
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：399 / 406
页数：8
相关论文
共 50 条
  • [41] The efficacy of atezolizumab plus bevacizumab in the treatment of unresectable hepatocellular carcinoma in cirrhotic and non-cirrhotic patients
    Aranda-Gutierrez, Alejandro
    Conde-Flores, Emilio
    Meraz-Brenez, Andres
    Escorza, Salvador
    Meneses-Medina, Monica I. Isabel
    Huitzil-Melendez, Fidel David
    de la Mora-Molina, Hector
    Rosas Camargo, Vanessa
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [42] ASSESSING ATEZOLIZUMAB PLUS BEVACIZUMAB TREATMENT FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA PATIENTS WITH ESOPHAGEAL-GASTRIC VARICES
    Tada, Fujimasa
    Hiraoka, Atsushi
    Hatanaka, Takeshi
    Tada, Toshifumi
    Kakizaki, Satoru
    Kumada, Takashi
    GASTROENTEROLOGY, 2024, 166 (05) : S1730 - S1730
  • [43] Efficacy of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma: a Meta-analysis
    Changez, Mah I. Kan
    Khan, Maimoona
    Uzair, Muhammad
    Tahir, Muhammad Fawad
    Mohsin, Maryam
    Hussain, Amna Faiyaz
    Saqib, Vania
    Molani, Muhammad Khizer
    Ahmed, Aisha Habib
    Khalid, Saad
    JOURNAL OF GASTROINTESTINAL CANCER, 2024, 55 (01) : 467 - 481
  • [44] Editorial: Predictive Factors and Survival Outcome of Conversion Therapy for Unresectable Hepatocellular Carcinoma Patients Receiving Atezolizumab and Bevacizumab: Comparative Analysis of Conversion, Partial Response and Complete Response Patients
    Gorgulho, Joao
    von Felden, Johann
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (10) : 1467 - 1468
  • [45] Neoadjuvant transarterial chemoembolization (TACE) plus PD-1 inhibitor bridging to tumor resection in intermediate-stage hepatocellular carcinoma patients
    Caihua Zhu
    Bing Dai
    Hua Zhan
    Ruoyu Deng
    Irish Journal of Medical Science (1971 -), 2023, 192 (3): : 1065 - 1071
  • [46] Prognostic Evaluation of Conversion Therapy following Hepatic Arterial Infusion Chemotherapy or Immunotherapy in Patients with Advanced or Transarterial Chemoembolization Unsuitable Intermediate-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study
    Kuo, Li-Fu
    Liu, Wen-Chun
    Li, Ming-Feng
    Huang, Fu-Huan
    Chou, Chu-Kuang
    Chen, Tsung-Hsien
    Tsai, Yi-Tseng
    Hsu, Ping-I.
    Li, Chao-Jen
    Wu, I. -Ting
    Tsai, Kun-Feng
    ONCOLOGY, 2024,
  • [47] Neoadjuvant transarterial chemoembolization (TACE) plus PD-1 inhibitor bridging to tumor resection in intermediate-stage hepatocellular carcinoma patients
    Zhu, Caihua
    Dai, Bing
    Zhan, Hua
    Deng, Ruoyu
    IRISH JOURNAL OF MEDICAL SCIENCE, 2023, 192 (03) : 1065 - 1071
  • [48] Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis
    Chuma, Makoto
    Uojima, Haruki
    Hattori, Nobuhiro
    Arase, Yoshitaka
    Fukushima, Taito
    Hirose, Shunji
    Kobayashi, Satoshi
    Ueno, Makoto
    Tezuka, Shun
    Iwasaki, Shuichiro
    Wada, Naohisa
    Kubota, Kousuke
    Tsuruya, Kota
    Shimma, Yoshimasa
    Hiroki, Ikeda
    Takuya, Ehira
    Tokoro, Chikako
    Iwase, Shigeru
    Miura, Yuki
    Moriya, Satoshi
    Watanabe, Tsunamasa
    Hidaka, Hisashi
    Morimoto, Manabu
    Numata, Kazushi
    Kusano, Chika
    Kagawa, Tatehiro
    Maeda, Shin
    HEPATOLOGY RESEARCH, 2022, 52 (03) : 269 - 280
  • [49] CLINICAL USEFULNESS OF MONITORING MUSCLE VOLUME DURING ATEZOLIZUMAB PLUS BEVACIZUMAB THERAPY IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA
    Matsumoto, Hiroaki
    Tsuchiya, Kaoru
    Nakanishi, Hiroyuki
    Hayakawa, Yuka
    Yasui, Yutaka
    Uchihara, Naoki
    Suzuki, Keito
    Tanaka, Yuki
    Miyamoto, Haruka
    Ishido, Shun
    Yamada, Michiko
    Keitoku, Taisei
    Nobusawa, Tsubasa
    Higuchi, Mayu
    Takaura, Kenta
    Tanaka, Shohei
    Maeyashiki, Chiaki
    Tamaki, Nobuharu
    Takahashi, Yuka
    Kurosaki, Masayuki
    Izumi, Namiki
    HEPATOLOGY, 2022, 76 : S1362 - S1363
  • [50] Risk factors for Early onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
    Ando, Yuwa
    Kawaoka, Tomokazu
    Kosaka, Masanari
    Shirane, Yuki
    Johira, Yusuke
    Miura, Ryoichi
    Murakami, Serami
    Yano, Shigeki
    Amioka, Kei
    Naruto, Kensuke
    Kosaka, Yumi
    Uchikawa, Shinsuke
    Kodama, Kenichiro
    Fujino, Hatsue
    Nakahara, Takashi
    Ono, Atsushi
    Murakami, Eisuke
    Yamauchi, Masami
    Okamoto, Wataru
    Takahashi, Shoichi
    Imamura, Michio
    Aikata, Hiroshi
    LIVER CANCER, 2023, 12 (03) : 251 - 261
12345